Search the Newsreel

Travere Therapeutics to Report Second Quarter 2026 Financial Results

Travere Therapeutics, Inc. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a …

TVTX|Travere Therapeutics Inc|Price:55.890|Chg%:-0.790

This article provides a comprehensive stock analysis of Travere Therapeutics Inc (TVTX), highlighting its strong fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite trading sideways recently, institutional ownership is very high, and multiple analysts rate the …

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders through potential self-dealing. The firm is encouraging long-term TVTX stockholders to contact them, suggesting they may be entitled …

Travere sets Aug. 4 webcast for results, business update

Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Travere Therapeutics Inc (TVTX), detailing its price momentum, support and resistance levels, and various technical indicators. The stock currently has a neutral signal based on moving averages and other technical indicators, trading between support at 53.12 and …

Investigation launched into Travere Therapeutics' officers for possible self-dealing breaches

Kuehn Law, PLLC has initiated an investigation into the officers and directors of Travere Therapeutics for potential breaches of fiduciary duties through self-dealing. This investigation could result in damages for shareholders and foster corporate governance reforms. Long-term shareholders are advised to contact the law …

Travere Therapeutics Inc (TVTX) Institutional Confidence

Travere Therapeutics Inc (TVTX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 4.06% quarter-over-quarter, with Fidelity Management & Research Company LLC and Fidelity Institutional Asset Management showing significant …

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

Guggenheim analyst Vamil Divan reiterated a Buy rating on Travere Therapeutics (TVTX) with a price target of $65.00. This follows similar optimism from TD Cowen, which also maintained a Buy rating with a $60.00 price target. The company recently reported a quarterly revenue of …

TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment

Travere Therapeutics' shares surged after the U.S. FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), a rare kidney disorder, making it the first approved treatment for the condition. Analysts are highly bullish, with Canaccord projecting peak sales of $547 million by 2032 and major …

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), McKesson (MCK) and Avita Medical (RCEL)

This article provides an overview of analyst ratings for three healthcare companies: Travere Therapeutics (TVTX), McKesson (MCK), and Avita Medical (RCEL). Travere Therapeutics received a Strong Buy consensus with a price target of $58.33, while McKesson also garnered a Strong Buy with an average …

Travere Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.71, Implies 4% Upside

Travere Therapeutics, Inc.'s average 12-month stock price target has been increased to $58.71 from $58.36, indicating a potential upside of approximately 4%. This updated target is based on estimates from 14 analysts, with forecasts ranging from $43 to $70 per share. The consensus rating …

RTRX5376243 Bond Profile — Key Metrics

This article provides key metrics for the Travere Therapeutics, Inc. (RTRX5376243) bond, including its coupon rate, issue and maturity dates, outstanding amount, and face value. It also details information about Travere Therapeutics, Inc. as a biopharmaceutical company focused on rare diseases.

RTRX5376243 Bond Risk Profile

This article provides a risk profile for the Travere Therapeutics, Inc. 2.25% 01-MAR-2029 bond (RTRX5376243). It highlights key metrics for credit risk assessment, including security level and issuer rating. The bond is listed on FINRA and indicates that the market is currently closed with …

Law firm probes Travere Therapeutics officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating whether officers and directors of Travere Therapeutics, Inc. breached their fiduciary duties through potential self-dealing. This probe could lead to damages and corporate governance reforms that would benefit shareholders. Long-term investors are encouraged to contact the law firm for …